Quadrant purchase adds CME muscle

Share this article:
Quadrant HealthCom plans to beef up its med ed offering through four titles recently acquired from Jobson.

“The idea is to integrate them into Quadrant and try to give them the kind of support they need to realize their potential,” said Steve Stoneburn, president and CEO of Quadrant. “We're optimistic we can continue to grow that business.”

The acquisitions broaden Quadrant's audience to 500,000 readers across 13 titles, bolstering its primary care portfolio and giving it entrée into the neurology, psychiatry, pulmonary and NP/PA specialty categories. The four titles include Clinician Reviews, Neurology Reviews, Neuropsychiatry Reviews and Pulmonary Reviews.

A fifth title included in the deal, Women's Health in Primary Care, will cease publication, with elements to be added to Quadrant's The Female Patient. Editor-in-chief Maura Griffith will serve as chief of content development activities at Quadrant Medical Education.

Roland DeSilva of DeSilva + Phillips, which brokered the deal for Quadrant, called it “an excellent strategic fit for Quadrant.”

Stoneburn said great synergies exist between the titles. “We've begun to develop a series of market-specific publications under the banner of Women's Health In…that utilizes the women's health content and branding but focus on more narrowly defined subjects,” he said.

Terms of the deal were not disclosed.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...